Premium
A novel multi‐kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K‐AKT pathway
Author(s) -
Hosaka Seiichi,
Horiuchi Keisuke,
Yoda Masaki,
Nakayama Robert,
Tohmonda Takahide,
Susa Michiro,
Nakamura Masaya,
Chiba Kazuhiro,
Toyama Yoshiaki,
Morioka Hideo
Publication year - 2012
Publication title -
journal of orthopaedic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1002/jor.22091
Subject(s) - pazopanib , synovial sarcoma , pi3k/akt/mtor pathway , sarcoma , cancer research , medicine , soft tissue sarcoma , angiogenesis , pharmacology , chemistry , pathology , signal transduction , cancer , biochemistry , sunitinib
Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti‐angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K‐AKT pathway was highly suppressed in pazopanib‐sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies. © 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:1493–1498, 2012